R
路演公司
OADSHOW COMPANIES

BFC Global Healthcare Investment Conference
January 6,2019
15:30-17:30 Company Roadshow

Room 1:

  • Time
    Company
    Company profile
    Speaker
  • 15:30–15:40
    Aduro
    Aduro Biotech, Inc. (NASDAQ: ADRO) is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases.
    Steve Isaacs, CEO
  • 15:40–16:00
    Dyadic
    ** Significant investment platform technology opportunity ** Dyadic leads the field driving down the cost of biological therapy development in alternative expression technologies. Title: "Disruptive C1 Technology To Make Biologic Vaccines & Drugs More Accessible & Affordable To Patients"
    Mark Emalfarb,CEO
  • 16:00-16:10
    CloudBreak
    Cloudbreak Therapeutics: Developing A Phase 3-ready, First-in-Class and First Drug Therapy to Treat Pterygium and Other Ocular Diseases
    Jinsong Ni, CEO
  • 16:10-16:20
    Ophthotech Corporation
    Ophthotech develops transformative gene therapies and novel therapeutics for debilitating retinal diseases
    Glenn Sblendorio, president & CEO
  • 16:20-16:30
    Virogin
    Virogen is a global leading innovative biotech company, focusing on oncolytic virus.
    Farzian Aminuddin,BD Senior Manager
  • 16:30-16:40
    Achillion Pharmaceuticals
    At Achillion, our principal focus is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and commercialization for patients with devastating disorders of the complement Alternative Pathway(AP).
    Tony Gibney,Chief Business Officer
  • 16:40-16:50
    SINNOWA
    SINNOWA is a professional Chinese IVD products developer & producer, key products including Aggrestar, which can prevent >82% thrombosis in advance & Chemifastar, which is accurate, convenient & complete test menu POCT/Lab fully auto biochemistry analyzer.
    Xin Xu, President & CEO
  • 16:50-17:00
    Hycor
    Hycor Biomedical is an in vitro diagnostics company focused on delivering innovative testing for allergy and autoimmune diseases.
    Fei Li, President & CEO
  • 17:00-17:10
    MatriVax
    Matrivax is a clinical-stage, biotechnology company developing proprietary antigens and vaccine delivery technologies targeting life-threatening pneumococcal pneumonia, C. difficile, and typhoid fever diseases.
    Kevin P. Killeen,CSO
  • 17:10-17:20
    Vigeo
    Vigeo is a clinical stage company focusing on the research and development of novel oncology therapeutic agents that suppress tumor growth and inhibit metastasis via reprogramming the tumor immune microenvironment.
    Jing Watnick, President & CEO
  • 17:20-17:30
    HawkEye Bio
    Hawkeye Bio provides a breakthrough breath testing technology to detect early signs of lung cancer.
    Andre de Fusco, CEO

Room 2:

  • Time
    Company
    Company profile
    Speaker
  • 15:30-15:40
    TCL medical imaging technology
    With the solid foundation of TCL Medical's good medical imaging products, TCL Medical Imaging Technology is newly established to carry out medical imaging center service business to provide professional and high-quality medical imaging diagnosis services.
    Hongliang Lu, CEO
  • 15:40-15:50
    Aucta Healthcare
    Aucta Pharmaceuticals is a technology based company focusing on the development and commercialization of Branded Specialty Products in CNS , Dermatology, and Pediatrics.
    Shoufeng Li,CEO
  • 15:50-16:00
    Asymchem
    Asymchem is a public(SZ:002821), USFDA inspected contract development and manufacturing organization focused on developing practical and sustainable processes for both clinical phase and commercial scale projects in the biopharmaceutical industry.
    James Gage, CSO
  • 16:00-16:10
    TenNor Therapeutics
    TenNor Therapeutics is a clinical-stage company with a unique, multi-targeting drug discovery platform and a strong, globally protected product development portfolio in the treatment of gastrointestinal tract infections, prosthetic joint infections, bacterial vaginosis, multidrug-resistant tuberculosis and multidrug-resistant Gram-negative bacterial infections.
    Zhenkun Ma, CEO
  • 16:10-16:20
    Adamerck
    Adamerck Pharmlabs is a high-tech pharmaceutical enterprise, dedicated to the research, development and industrialization of innovative peri-surgery relevant drugs.
    Shuning Zhang, Medical Director
  • 16:20-16:30
    Phagelux
    Phagelux is utilizing phages, lysins and other biological solutions to create adjuncts and alternatives to antibiotics, particularly targeting antibiotic resistant strains of bacteria.
    Mark Engel,CEO
  • 16:30-16:40
    Transcenta
    Transcenta Holding Ltd. is a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics,particularly in the field of antibody-based therapeutics for cancer and other diseases.
    Xueming Qian, CEO
  • 16:40-16:50
    Phanes
    Phanes Therapeutics is an emerging leader in developing innovative mAb/bispecific/guided mAb therapeutics, with focus on oncology, NASH and eye diseases.
    Ming Wang, CEO
  • 16:50-17:00
    Bostal
    Bostal is a high technology company based in Guangzhou, focusing on formulation CRO/CMO business and generic and 505b(2) drugs. Bostal's core competency is high end formulation technology, including DR, CR, microsphere, liposome, Nano crystal, and so on
    Ron Liu, CEO
  • 17:00-17:10
    Impact Therapeutics Inc
    IMPACT is a biotech company, focused on DNA damage Best-in-class drugs R&D.Its core drug, PARP inhibitor will be in Phase II soon. IMPACT has been invested by many institutional investors,such as LAV,decheng, and Wuxi etc.
    Jun Bao, CEO
  • 17:10-17:20
    CARsgen
    CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development and commercialization of First-in-Class and Best-in-Class CAR-T therapeutics.
    Zonghai Li, CEO
  • 17:20-17:30
    Puxiang Hospital
    Pu Xiang is a specialty hospital focusing on oncology and plays the leading role among Chinese community healthcare organizations.
    Qingliang Zhang, Executive President
注册参会